Malaria parasites carried by mosquitoes kill more than 660,000 people each year
A novel malaria vaccine developed at Oxford University has shown promising results in the first clinical trial to test whether it can protect people against the mosquito-borne disease. The trial was carried out in Oxford by researchers led by Professor Adrian Hill of the Jenner Institute at Oxford University, along with colleagues from the biotechnology company Okairos. Some of the adult volunteers were completely protected against malaria in this initial study of the vaccine's efficacy. It's the first time that a vaccine has been shown to have an effect through a sufficiently high immune response involving cells called CD8 T cells. It is CD8 immune cells that are seen to mount a protective response against malaria in studies in mice. Every existing vaccine in use - bar one - generates antibodies. But there are two arms to the body's immune system for fighting infection: antibodies and'T cells.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
